|
PYROXD1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.41570000000701E-06 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
8.0846999999995E-05 |
| Normal-vs-Stage2 |
1.318190E-03 |
| Normal-vs-Stage3 |
5.53560000060571E-08 |
| Normal-vs-Stage4 |
2.03919999774982E-08 |
| Stage1-vs-Stage2 |
8.729800E-01 |
| Stage1-vs-Stage3 |
2.720400E-02 |
| Stage1-vs-Stage4 |
1.239890E-02 |
| Stage2-vs-Stage3 |
1.795570E-01 |
| Stage2-vs-Stage4 |
6.728000E-02 |
| Stage3-vs-Stage4 |
4.244600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.1323000032325E-08 |
| Normal-vs-AfricanAmerican |
5.827500E-02 |
| Normal-vs-Asian |
7.98550000000731E-05 |
| Caucasian-vs-AfricanAmerican |
3.418000E-01 |
| Caucasian-vs-Asian |
4.005200E-01 |
| AfricanAmerican-vs-Asian |
6.573200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.83370000020433E-07 |
| Normal-vs-Female |
6.22810000017182E-07 |
| Male-vs-Female |
3.722600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.591200E-04 |
| Normal-vs-Age(41-60Yrs) |
3.05659999533248E-08 |
| Normal-vs-Age(61-80Yrs) |
1.84957999999069E-05 |
| Normal-vs-Age(81-100Yrs) |
1.752190E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.774300E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.855200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
5.772800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
5.805600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.697000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.669400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.780200E-02 |
| Classical-VS-Follicular |
1.900080E-02 |
| Classical-VS-Other |
4.970400E-01 |
| Classical-VS-Normal |
4.96319999987449E-07 |
| Tall-VS-Follicular |
4.044700E-04 |
| Tall-VS-Other |
6.311400E-01 |
| Tall-VS-Normal |
1.48649999975881E-07 |
| Follicular-VS-Other |
2.197800E-01 |
| Follicular-VS-Normal |
6.184000E-02 |
| Other-VS-Normal |
7.155300E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.00429999988694E-07 |
| Normal-vs-N1 |
1.65397999999373E-05 |
| N0-vs-N1 |
5.780400E-01 |
|
|
